Steve Stivers: “I thank Ranking Member Walden for yielding, and I commend him for his efforts to limit drug prices and continue…”

“I thank Ranking Member Walden for yielding, and I commend him for his efforts to limit drug prices and continue innovation. I have a concern about the increased costs that both H.R. 3 and H.R. 19, as well as Senate proposals, could have on small manufacturers through the part D redesign. These small manufacturers often serve the Low-Income Subsidy population that are our most vulnerable, and it would disproportionately affect their access to lifesaving and life-changing medications, such as drugs for mental illness and addiction. H.R. 3 is catastrophic to this population. Madam Chair, I ask to enter into a colloquy with the gentleman from Oregon and seek his commitment to ensure small manufacturers and the LIS population are not inadvertently penalized as this process moves forward of our alternative.”